With the S&P 500 rallying sharply off the March lows, the key is not to, "get swept away by some of these momentum stocks and stocks that have been moving because those could turn around and end up burning people," say Bob Auer, portfolio manager of the Auer Growth Fund.
Auer preaches investor discipline and has a keen eye for fundamentals.
Thanks to his stock picking strategy the fund gained 31% in the second quarter and Lipper ranked it the #1 multi-cap growth fund over that same period.
For those that missed his last appearance in June, the Auer Growth Fund only buys stocks that meet the following criteria:
Those rules have him buying shares of USEC Inc. – the country's sole provider of enriched uranium for nuclear power plants. USEC recently signed a deal with Exelon Generation Co. valued at nearly $1.2 billion. The stock's more than doubled since hitting a low of $2.58 last November but remains well below the $24 per share it traded at in the middle of 2007.
Auer still likes Cubist Pharmaceuticals, a name he mentioned this summer. The company sells Cubicin, an antibiotic that treats the methicillin resistant Staphylococcus aureus (MRSA).
Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes for NASDAQ, NYSE and Amex. See also delay times for other exchanges. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. Fundamental company data provided by Capital IQ. Financials data provided by Edgar Online. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and Morningstar Index data provided by Morningstar, Inc. Analyst estimates data provided by Thomson Financial Network. All data provided by Thomson Financial Network is based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no way endorses the validity of such data. Yahoo! and ThomsonFN shall not be liable for any actions taken in reliance thereon. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.